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Abstract
Background: Human cytomegalovirus (CMV) infection still causes significant morbidity and mortality after allogeneic 
hematopoietic stem cell transplantation (HSCT). Therefore, it is extremely important to diagnosis and monitor active 
CMV infection in HSCT patients, defining the CMV DNA levels of virus replication that warrant intervention with antiviral 
agents in order to accurately prevent CMV disease and further related complications.
Methods: During the first 150 days after allogeneic HSTC, thirty patients were monitored weekly for active CMV 
infection by pp65 antigenemia, nested-PCR and real-time PCR assays. Receiver operating characteristic (ROC) plot 
analysis was performed to determine a threshold value of the CMV DNA load by real-time PCR.
Results: Using ROC curves, the optimal cutoff value by real-time PCR was 418.4 copies/104 PBL (sensitivity, 71.4%; 
specificity, 89.7%). Twenty seven (90%) of the 30 analyzed patients had active CMV infection and two (6.7%) developed 
CMV disease. Eleven (40.7%) of these 27 patients had acute GVHD, 18 (66.7%) had opportunistic infection, 5 (18.5%) had 
chronic rejection and 11 (40.7%) died - one died of CMV disease associated with GVHD and bacterial infection.
Conclusions: The low incidence of CMV disease in HSCT recipients in our study attests to the efficacy of CMV 
surveillance based on clinical routine assay. The quantification of CMV DNA load using real-time PCR appears to be 
applicable to the clinical practice and an optimal cutoff value for guiding timely preemptive therapy should be 
clinically validated in future studies.
Background
Hematopoietic stem cell transplantation (HSCT) is an
important therapeutic tool for treating malignant and
non-malignant disorders, and the human cytomegalovi-
rus (CMV) reactivation is common in these cases due to
the immunocompromised state of patients [1].
Monitoring of its reactivation and preemptive or pro-
phylactic treatment using ganciclovir are critical for
HSCT recipients. However, because of the myelotoxicity
of ganciclovir and its prolongation of periods of neutro-
penia, the prognosis in patients at low risk of developing
CMV disease is not necessarily improved. Identification
of patients at high risk of developing CMV is therefore
believed to be important in management of HSCT recipi-
ents [2].
Despite major advances in prevention and preemptive
treatment, CMV infection still causes significant morbid-
ity and mortality following allogeneic hematopoietic stem
cell transplantation (HSCT) [3] and occurs in 50-90% of
allogeneic transplant recipients [4].
While detection of CMV pp65  antigenemia is still
widely used for monitoring CMV infection and guide
preemptive therapy in patients at risk of developing CMV
disease [5,6], the quantification of CMV DNA in blood by
PCR is emerging as an alternative to the pp65 antigene-
mia assay and may soon become the standard for the sur-
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veillance of CMV infection in allogeneic HSCT recipients
[7], because it presents several advantages over the pp65
antigenemia assay, including an increased sensitivity for
the detection of CMV reactivation, the reliable detection
of CMV reactivation during severe neutropenia in the
early post-transplant period, the shorter time required
for the procedure, and the convenient processing of large
numbers of specimens [8].
The aim of this study was to diagnosis and monitor
active CMV infection in allogeneic HSCT patients. In
addition, we have determined the proper cutoff level of
CMV DNA load by real-time PCR for preemptive ther-
apy, in order to switch the monitoring method from the
pp65 antigenemia assay to real-time PCR method.
Methods
Patients
Between August 2006 and September 2008, a total of 558
consecutive blood samples were received by our Labora-
tory for the simultaneous determination of pp65 antigen-
emia, nested-PCR and real-time PCR in leukocytes. The
samples came from 30 adult allogeneic HSCT recipients
(17 males and 13 females; median age: 40.5, range: 16-56)
with human leukocyte antigen (HLA) identical sibling
donors at risk for CMV infection (CMV seropositive
donor and/or recipient) at the Bone Marrow Transplant
Unit, Hemocenter, University of Campinas - Unicamp,
SP, Brazil (table 1). The median number of samples per
patient was 20 (range: 5-23). These patients were pro-
spectively monitored for active CMV infection at weekly
intervals from D+0 to D+150 post-transplant. The proto-
col was designed in accordance with the requirements for
research involving human subjects in Brazil, was
approved by the Institutional Ethics Committee and an
informed written consent was received from each patient.
Management of CMV infection and disease
Active CMV infection, CMV recurrence and CMV dis-
ease were defined according to published recommenda-
tions [9].
Active CMV infection is defined as isolation of CMV
virus or detection of viral proteins or nucleic acid from
any body fluid or tissue specimen. CMV recurrence is
defined as a new detection of CMV infection in a patient
previously diagnosed with infection and in whom virus
was not detected for an interval of at least four weeks
during active surveillance. CMV disease, which was
defined by immunohistochemical analysis of biopsy spec-
imens, is followed by clinical signs and symptoms, such
as: unexplained fever (> 38°C), leukopenia (white blood
cells < 3.5 × 109/L) and/or thrombocytopenia (platelet
count < 100 × 109/L), gastrointestinal symptoms, arthral-
gia, hepatitis, enteritis, retinitis, pneumonitis, colitis,
oesophagitis, encephalitis [10]. Probable CMV disease is
Table 1: Demographic characteristics of the patients
Characteristic
Age - median in years (range) 40.5 (16-56)
Sex - male/female 17/13
Underlying disease - n (%)
Malignant disease
Acute lymphocytic leukemia (ALL) 4 (13.3%)
Acute myelogenous leukemia (AML) 10 (33.3%)
Chronic lymphocytic leukemia (CLL) 1 (3.3%)
Chronic myelogenous leukemia 
(CML)
4 (13.3%)
Non-Hodgkin's lymphoma (NHD) 2 (6.7%)
Hodgkin's disease (HD) 3 (10%)
Multiple myeloma (MM) 1 (3.3%)
Myelofibrosis 2 (6.7%)
Non-malignant disease
Severe aplastic anaemia (SAA) 3 (10%)
Acute GVHD - (n%) 11 (36.7%)
Pretransplant CMV sorostatus - (n%)
D+/R+ 30 (100%)
Conditioning regimen - (n%)
Myeloablative transplant
BU + FLU 7 (23.3%)
BU + Cy 6 (20%)
BU+ Cy + VP-16 3 (10%)
Cy + VP-16 + TBI 2 (6.7%)
Cy + TBI 1 (3.3%)
Non-myeloablative transplant
FLU + TBI 9 (30%)
FLU + TBI + ARA-C 1 (3.3%)
GVHD prophylaxis - (n%)
CsP 2 (6.7%)
CsP + MMF 7 (23.3%)
CsP + MTX 20 (66.7%)
CsP + MTX + Mitoxantrone + Cy 1 (3.4%)
Stem cell source
Bone marrow 15 (50%)
Peripheral blood 15 (50%)
Deaths 13 (43.3%)
GVHD (Graft-versus-host disease); D (Donor); R (Recipient); BU 
(Bussulfan); FLU (Fludarabine); Cy (Cyclophosphamide); VP-16 
(Etoposide); TBI (Total body irradiation); ARA-C (Cytarabine); CsP 
(Cyclosporine); MMF (Mycophenolate mofetil); MTX 
(Methotrexate).Peres et al. BMC Infectious Diseases 2010, 10:147
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defined when clinical signs and symptoms are present,
but without accomplishment of biopsy.
Therapy
Preemptive therapy was used to prevent CMV disease
and was initiated upon a positive pp65 cell/3 × 105 PML
result ≥1 and/or two or more consecutive positive
nested-PCR results. Active CMV infection was treated
with GCV (5 mg/Kg twice daily, i.v) for seven days, fol-
lowed by a maintenance dose of 5 mg/Kg/day, i.v., three
times a week for four weeks, and CMV disease was
treated with GCV (5 mg/Kg twice daily, i.v) for 21 days,
followed by a maintenance dose of 5 mg/Kg/day, i.v.,
three times a week for four weeks.
Specimen processing
A 12 mL of EDTA-treated blood was collected from each
patient. Four mL were used for CMV pp65 antigenemia
assay and processed within 6 hours. Eight mL were used
for nucleic acid extraction by manual phenol-chloroform
method.
CMV pp65 antigenemia assay
Antigenemia is based on immunocytochemical detection
of the early structural, lower matrix protein (pp65) in
polymorphonuclear leukocytes (PML), as described by
Van der Bij et al. [10], with some modifications, as
described by Bonon et al. [11]. Blood samples were col-
lected in EDTA-containing tubes and transferred to the
laboratory within 6 hours. Leukocytes were isolated by
dextran sedimentation method, followed by erythrocyte
lysis. The cell pellet was suspended in phosphate-buff-
ered saline (PBS), and the polymorphonuclear leukocytes
(PML) were then centrifuged to prepare cytospin slides (3
× 105 PML per slide). The slides were air-dried and fixed
in formaldehyde, then immunostained with monoclonal
antibodies (Iq Products, Netherlands), and reacted with
peroxidase-labeled anti-mouse conjugate (HRP, Biotest,
Dreieich, Germany). The test was carried out in dupli-
cate. Results were expressed as number of positive cells
per 3 × 105 PML.
Nucleic acid extraction by manual phenol-chloroform 
method
CMV DNA was extracted from peripheral blood col-
lected in EDTA-containing tubes. Erythrocytes and leu-
kocytes were lysed. The sample was transferred to a tube
containing 400 μl of extraction buffer (Tris-HCl [10 mM,
pH 7.6], KCl [10 mM], MgCl2 [10 mM], NaCl [0.4 M],
EDTA [2 mM]) and 25 μl of sodium dodecyl sulfate [10%],
and incubated at 55°C for 30 minutes. The supernatant
was then purified by phenol-chloroform isoamilic alcohol
(24:1), followed by purification with chloroform isoamilic
alcohol (24:1). DNA was precipitated with ethanol, resus-
pended in 25 μl of distilled water and stored at -20°C until
use. These extracted DNA samples were used for both
qualitative (nested-PCR) and quantitative PCR (real-time
PCR) assays.
Nested-PCR
CMV DNA in blood specimens was detected by nested-
PCR using primers, as described by Demmler et al. [12]
and Shibata et al. [13]. CMV DNA was extracted from
peripheral blood by a manual phenol-chloroform
method. The primers were selected from the MIE region
of CMV AD169. The size of PCR amplification products
was 159 base pairs. The same protocol was used to
amplify the human β-globin gene sequence to guarantee
the quality of the extracted DNA. All experiments had
two negative controls (one without DNA and the other
with a human PBL DNA preparation known to be nega-
tive for CMV DNA) and one positive control (by CMV
strain AD169 aliquot).
Real-time PCR
The PCR primers and probe sequences were selected
from the US17 region of CMV strain AD169. The for-
ward and reverse CMV primers were 5' GAAGGTG-
CAGGTGCCCTG 3' and 5' GTGTCGACGAACGAC
GTACG 3', respectively. The TaqMan®  probe selected
between both primers was fluorescence labeled with 6-
carboxyfluorescein at the 5' end as the reporter dye and
6-carboxytetramethylrhodamine at the 3' end as the
quencher (5' FAM ACGGTGCTGTAGACCCGCATA-
CAAA TAMRA3'). A search of databases indicated that
neither the primers nor the probe shared significant
homology with any known nucleotide sequence. The oli-
gonucleotide synthesis was provided by IDT®, Inc (Inte-
grated DNA Technologies). The reference standard curve
for calibration of CMV copy numbers was constructed
inserting the US17 amplicon, respectively, into a plasmid
PROMEGA P GEM - T Easy Vector System I (Promega),
using a cloning strategy, and propagated in competent
Escherichia coli cells. For this construct, plasmid DNA
w a s  p u r i f i e d  o n  c o l u m n s  w i t h  S V  W i z a r d  P u r i f i c a t i o n
System (Promega), DNA concentration was determined
by measuring OD260, using a NanoDrop ND-1000 spec-
trophotometer and the corresponding copy number was
then calculated. The construct was serially diluted in
water within a range of 102 to 107 copies/μl. The real-time
PCR was performed with a 12 μl mixture containing: 3
mM MgCl2; 10 μM dATP, dCTP, dGTP, dTTP; 5 U/μl of
Platinum Taq (Invitogen), 60 ng DNA templates, 150 nM
of the forward and reverse primers (CMVUS17F-
CMVUS17R for CMV detection) and 2 μM of the specific
TaqMan® CMV probe (PE Applied Biosystems). The sin-
gle PCR was performed in 96-well microliter plates under
the following conditions: 1 cycle at 50°C for 2 minutes,
95°C for 10 minutes and 45 cycles at 95°C for 15 secondsPeres et al. BMC Infectious Diseases 2010, 10:147
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and 60°C for 1 minute. The β-actin gene amplification
was performed under the same PCR conditions described
above for the reaction control using 2 μM β-actin probe
(FAM™ Probe), 3 μM β-actin forward primer, and 3 μM β-
actin reverse primer (TaqMan® β-actin detection reagents
- Applied Biosystems).
Statistical analysis
Receiver operating characteristic (ROC) plot analysis was
performed to determine a threshold value of the CMV
DNA load in peripheral blood leukocytes (PBL) for initi-
ating preemptive treatment. Using 1 pp65 antigen posi-
tive cell/3 × 105 PML as the reference standard, the best
sensitivity and specificity were calculated to determine
optimal cutoff value for CMV DNA copies. Probability
density function was used to describe the probability of
occurrence of active CMV infection during the period of
monitoring. A contingency table analysis was used to cal-
culate the sensitivity, specificity and positive (PPV) and
negative predictive values (NPV) of nested-PCR and real-
time PCR using pp65 antigenemia ≥ 1 positive cell as the
reference standard. The Fisher's exact test was used to
calculate the probability of association among active
CMV infection and CMV disease, acute graft-versus host
disease (GVHD), opportunist infection, graft rejection
and death. Statistical package that has been used is R
Development Core Team (2009).
Results
Active CMV infection
In this study, we considered active CMV infection detec-
tion one or more positive cells by pp65 antigenemia assay
and/or two or more consecutive positive nested-PCR
and/or load CMV ≥ 418.4 copies/104 peripheral blood
leukocytes (PBL) by real-time PCR. The highest inci-
dence of active CMV infections occurred during the sec-
ond post-transplant month (31 - 60 days) with a
percentage of active CMV infection of 76.7% and maxi-
mum value of probability density of 0.01 at day 44.4 after
HSCT (figure 1). Twenty seven (90%) of the 30 analyzed
patients had active CMV infection, nine (30%) had recur-
rence of CMV infection, two developed probable CMV
disease (6.7%) and two (6.7%) developed CMV disease.
Twenty one (77.8%) of the 27 patients who had active
CMV infection received preemptive antiviral therapy, 11
(40.7%) had occurrence of acute GVHD, 18 (66.7%) had
opportunist infection, five (18.5%) had chronic rejection
and 11 (40.7%) died (table 2).
Incidence and outcome of CMV disease
Two of the 30 patients developed CMV disease after a
median of 86.5 days (range 80-93 days) from HSCT. Both
had gastrointestinal disease with manifestation of CMV
infection in gastrointestinal tract biopsy specimens, and
one of them died due to CMV disease associated with
GVHD and bacterial infection at 252 days after HSCT.
Two patients had probable CMV disease after a median
of 70.5 days (range 30-111 days) from HSCT, one of them
had gastrointestinal infection and the other one had
interstitial pneumonia, both without accomplishment of
biopsy. The patient who had interstitial pneumonia died
of this cause at 33 days after HSCT.
Comparisons of the three assays
A total of 558 weekly samples were obtained from 30
patients and analyzed by pp65 antigenemia, nested-PCR
and real-time PCR assays. A total of 35 samples obtained
from 13 patients were positive by pp65 antigenemia, 154
samples from 21 patients were positive by nested-PCR
and 78 samples from 23 patients were positive by real-
time (using the cutoff value of 418.4 copies/104 PBL). Ten
patients were positive by the three assays (pp65 antigene-
mia, nested-PCR and real-time PCR), two patients were
positive by pp65  antigenemia and real-time PCR, one
patient was positive by pp65  antigenemia and nested-
PCR, seven patients were positive by nested-PCR and
real-time PCR, four patients were positive by real-time
PCR only, and three patients were positive by nested-
PCR only (figure 2). Using pp65 antigenemia as the refer-
ence standard, the sensitivity and specificity of nested-
PCR were 84.6% and 41.2% and the positive predictive
value (PPV) and the negative predictive value (NPV) were
52.4% and 77.8%, respectively. The real-time PCR showed
a sensitivity of 92.3%, specificity of 35.3%, PPV of 52.2%
and NPV of 85.7%, using the cutoff value of 418.4 copies/
104 PBL (table 3).
Figure 1 Probability density of active CMV infection. Seasonal vari-
ation of active CMV infection over a 150 days after HSCT period. The 
highest incidence occurred during the second post-transplant month 
with maximum value of probability density of 0.010 at day 44.4 after 
HSCTPeres et al. BMC Infectious Diseases 2010, 10:147
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Time to detection of active CMV infection by pp65 
antigenemia, nested-PCR and real-time PCR in 
transplanted patients
Thirteen (43.3%) of the 30 patients monitored developed
positive  pp65  antigenemia after a median of 40 days
(range 29-152 days), 21 (70%), developed a consecutive
positive nested-PCR after a median of 33 days (range 0-
126 days), while 23 (76.7%) developed positive real-time
PCR after a median of 40 days (range 0 - 119 days) from
HSCT (table 4).
Determination of CMV DNA cutoff value for real-time PCR
Using ROC curves, optimal cutoff points for viral load by
real-time PCR in peripheral blood leukocytes (PBL) were
calculated for one specific pp65  antigenemia value: ≥1
positive cell/3 × 105 PML. The optimal cutoff value for
real-time PCR in peripheral blood leukocytes was 418.4
copies/104 PBL (sensitivity 71.4%; specificity 89.7%) (Fig-
ure 3).
Discussion
We have established a new method of diagnosis of CMV
infection using real-time PCR based on TaqMan® technol-
ogy. Several studies, such as Machida et al. [2], reported
that PCR is a very useful method for early diagnosis of
CMV disease, but it may be frequently too sensitive for
clinical use and do not necessarily indicate an imminent
risk of developing CMV disease. However, we overcame
this problem using receiver operating characteristic
(ROC) plot analysis to determine a threshold value of the
CMV DNA load for initiating treatment. The sensitivities
and specificities for US17 were calculated to determine
optimal cutoff value for CMV DNA copies.
In this study, we used three different detection assays
(pp65 antigenemia, nested-PCR and real-time PCR) for
monitoring active CMV infection in allogeneic stem cell
transplant recipients. We could observe a high incidence
of active CMV infection occuring during the second post-
transplant month (31 - 60 days), with a maximum value of
probability density 44.4 days after HSCT, corroborating
data in the literature, which reports that the highest inci-
dence of CMV infections occur during the first three
post-transplant months [14], secondary to the greatest
degree of immunosuppression [15,16].
The incidence of active CMV infection was high (27 of
30 patients, 90%) after a median of 33 days (range 0-119
days), and only two (6.7%) patients had CMV disease,
both in the gastrointestinal tract. Only one (3.3%) of 30
patients monitored in this study died of CMV disease, in
agreement with the low rates of CMV-related mortality
cited in published reports [17,18].
The incidence of active CMV infection was comparable
to that found in previous reports on HSCT. Bonon et al.
[11] noted active CMV infection in 55 (79.7%) of 69 ana-
lyzed patients, considering that six (8.7%) developed
CMV disease. Gentile et al. [19] evaluated 38 HSCT
recipients. Among them, 25 (70%) had active CMV infec-
tion and three (7.9%) were pathologically diagnosed with
CMV colitis.
Table 2: Occurrence of active CMV infection versus complications associated with HSCT
Active CMV Infection
Positive Negative Median (days) Range p*
Recurrence of Active CMV Infection 9/27 0/3 114 46 - 152 NS
CMV Disease 2/27 0/3 86.5 80 - 93 NS
Acute GVHD 11/27 0/3 77 26 - 96 NS
Opportunist Infection 18/27 3/3 20 3 - 348 NS
Graft Rejection 5/27 0/0 166 51 - 199 NS
Death 11/27 2/3 203 33 - 534 NS
CMV, human cytomegalovirus; GVHD, graft-versus host disease; NS, not significant; *Fisher's exact test.
Figure 2 Active CMV infection stratification by diagnostic test. 
Absolute and relative number of patients with positive CMV samples 
stratified for diagnostic assays (n = 27). Active CMV infection: ≥ 1 cell 
pp65 positive/3 × 105 PML, and/or 2 or more consecutive positive nest-
ed-PCR and/or load CMV ≥ 418.4 copies/104 PBL by real-time PCR. All 
tests were performed weekly from aliquots of the same blood samplePeres et al. BMC Infectious Diseases 2010, 10:147
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The high incidence of active CMV infection detected in
our patients is associated to no prophylactic treatment
and pretransplant CMV sorostatus of donors and recipi-
ents (D+/R+:100%). This group is identified as high-risk
patients to develop active CMV infection and CMV dis-
ease [20].
In this study, the absence of statistical significance
among active CMV infection and recurrence of CMV
infection, CMV disease, GVHD, opportunist infection,
chronic rejection and death may be influenced by the
small number of patients, the preexisting heterogeneity of
conditioning regimens, GVHD prophylaxis and hemato-
logical diseases, according to Gentile et al. [19].
Several studies have attempted to determine a CMV
DNA copy number equivalent to the levels of pp65 anti-
genemia and to implement CMV PCR as pp65 antigene-
mia in clinical practice [21]. Identification of a cutoff level
for real-time PCR assay would be an important indicator
of time to initiate an anti-CMV treatment [20], would
reduce the number of patients treated with preemptive
therapy who are not destined to develop CMV disease [6]
and the duration of preemptive therapy might be short-
ened by real-time PCR guided manner, because more
r a p i d  n e g a t i v e  c o n v e r s i o n  o f  v i r a l  r e a c t i v a t i o n  w a s
detected using this assay [8].
Choi et al. [8] suggested cutoff values of approximately
3 × 104 copies/mL in low-risk patients and of approxi-
mately 2 × 104 copies/mL in high-risk patients. Cariani et
al. [22] defined a positive cutoff value equivalent to 9960
copies/mL in HSCT. Garrigue et al. [23] reported that
thresholds of 10 and 50 positive cells/2 × 105 cells were
equivalent to 3.3 log10 copies/mL (2000 copies/mL) and
3.8 log10 copies/mL (6300 copies/mL), respectively. Kal-
poe et al. [24] suggested that preemptive therapy could be
initiated at CMV DNA load of 1000 copies/mL and then
increased by 10-fold per week at the first episode of CMV
reactivation. Lilleri et al. [25] suggested a cutoff value of
10000 copies/mL for initiating preemptive therapy in
HSCT recipients, and Graffari et al. [21] previously
defined a positive cutoff value of greater than 1000 cop-
ies/2 × 105 PBL in HSCT recipients.
In our study, we have calculated the optimal cutoff viral
load using ROC curve for a pp65 antigenemia value ≥1
positive cell. The analysis of data indicated that a CMV
DNA level of 418.4 copies/104 PBL was a convenient
value for discriminating between latent infections and
those requiring preemptive therapy. This specific pp65
antigenemia value has been used in our Centre as the
threshold for initiating preemptive therapy in HSCT
recipients with an incidence of CMV disease lower than
7%.
It is difficult to compare data from different centers
because real-time PCR methods are not well standard-
ized and use different target sequences, primer sets, and
extraction and detection methods, which result in differ-
ent analytical performances [7].
Given the lack of standardization of CMV monitoring
by real-time PCR, the cutoff definition for predicting
CMV disease and initiating preemptive antiviral therapy
remain a question [26]. The results shows that studies
evaluating this assay are highly heterogeneous, there is no
available international standard for CMV PCR, and each
study determined its own assays characteristics for their
own setup [23].
Table 3: Results of contingency table analysis using pp65 antigenemia as a reference standard
Nested-PCR Real-time PCR
Sensitivity 84.6% 92.3%
Specificity 41.2% 35.3%
PPV 52.4% 52.2%
NPV 77.8% 85.7%
PPV, positive predictive value; NPV, negative predictive value.
Table 4: Time to until detection of active CMV infection by pp65 antigenemia, nested-PCR and real-time PCR
N° Patients Median (days after HSCT) Range
Patients with active CMV infection 27 (90%) 33 0 - 119
Positive pp65 antigenemia (%) 13 (43.3%) 40 29 - 152
Positive nested-PCR (%) 21 (70%) 33 0 - 126
Positive real-time PCR (%) 23 (76.7%) 40 0 - 119
CMV, human cytomegalovirus.Peres et al. BMC Infectious Diseases 2010, 10:147
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Most reports on detecting CMV DNA by real-time
PCR have used 'in-house' assays with variable primers for
the same gene or different genes (e.g. the immediate early
CMV gene or the CMV DNA polymerase gene), making
it difficult to extrapolate results from one institution to
another [21,27]. Assay sensitivity varies greatly depend-
ing on the methodology used. Commercial diagnostic
tests could avoid variability between home-brewed
assays, improving reproducibility and standardization of
the results [28].
Further studies to correct current cutoff value and to
validate the optimal cutoff value for the initiation of pre-
emptive therapy are currently underway at our HSCT
center.
Conversely, we thought that high negative predictive
value (85.7%) could allow us to avoid unnecessary pre-
emptive therapy with a fair aliquot of patients. The opti-
mal cutoff value by real-time PCR for therapeutic
intervention needs to be clearly defined to determine the
maximal specificity for CMV disease, and to define its
value for prognosis and use in therapeutic clinical trials.
Conclusion
The low incidence of CMV disease in HSCT recipients in
our study attests to the efficacy of CMV surveillance,
based on the pp65  antigenemia assay and nested-PCR
(assay used in clinical routine). The quantification of
CMV DNA load using real-time PCR appears to be appli-
cable to the clinical practice and an optimal cutoff value
for guiding timely preemptive therapy should be clinically
validated in future studies. For this reason, we think that
real-time PCR can be used complementarily to pp65 anti-
genemia screening to monitor preemptive therapy for
presenting high sensitivity, in addition to be an alterna-
tive for CMV diagnoses in cases of samples collected
before engraftment due to the lack of leukocytes during
the period of aplasia, in neutropenic patients and in
occurrence of CMV gastrointestinal disease.
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